Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
BioSpace7h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Inventory issues hobble Lilly sales
Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
Hosted on MSN7h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Investor's Business Daily on MSN22h
Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook
Eli Lilly stock reversed higher Thursday on its upbeat outlook despite lighter-than-expected fourth-quarter sales of its well-known weight-loss and diabetes drugs.Please watch the video at ...
Honor a loved one through Hearts Remembered
Dr. Tara Narula shares all the things she'd never do as a cardiologist in order to look out for her heart health. Could a ...
TVA fiscal numbers for final quarter of 2024
The Tennessee Valley Authority released its fiscal numbers for the final quarter of 2024.